C
Cognivia
Cognivia helps clinical trials manage key sources of data variability with predictive algorithms and patient psychology tools
About Cognivia
Cognivia, formerly known as Tools4Patient, is a company that provides analytical tools to optimize and accelerate the clinical development of new medicines. The company's core technology combines the quantification of patient psychology with artificial intelligence and machine learning to improve the measurement of drug efficacy. This approach aims to make patient behavior and drug responses more predictable, thereby de-risking the drug development process.
Cognivia's platform is designed to identify and manage key sources of variability within clinical trial data. By doing so, it helps pharmaceutical and biotech companies to make more confident and informed decisions during clinical development. The company's solutions are applicable to a wide range of therapeutic areas and are intended to ultimately accelerate patient access to new therapies.
In April 2024, Cognivia announced that it had secured a strategic investment of €15.5 million. This funding is intended to further empower the company's development of AI and machine learning solutions for the pharmaceutical and biotech clinical research sectors. The company's business model is centered around its patented platform technologies, which it commercializes to its clients in the drug development industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Mont-Saint-Guibert, Belgium
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 65.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Patient Care, Core AI, Tech for Biotech and Pharma, Biotech and Pharma, AI Drug Discovery, Techbio, Woman Founder
- Technology
- Artificial Intelligence
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Apr 2024 | $17M | $68M | SFPIM · Wallonie Entreprendre · WE Venture · Vesalius Biocapital Partners | ↗ |
| LATE VC✓Equity / VC | Dec 2021 | $4.9M | $22M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Cognivia is 290 monthly website visits, down 91.5% over the last three months. Cognivia's team declined 10.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Sambrinvest- JDJean-Pierre Delwart
Innovation Fund | Brussels
Series B and later4 investors entered at this stage
SFPIM
Wallonie Entreprendre
WE Venture
Vesalius Biocapital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cognivia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cognivia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.